14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $225.62 $260.34 Thursday, 2nd May 2024 UTHR stock ended at $258.13. This is 1.17% more than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 2.47% from a day low at $254.06 to a day high of $260.34.
90 days $208.62 $260.34
52 weeks $204.44 $261.48

Historical United Therapeutics Corporation prices

Date Open High Low Close Volume
Feb 21, 2024 $219.71 $227.75 $214.52 $219.18 610 127
Feb 20, 2024 $214.88 $217.75 $213.75 $214.16 576 447
Feb 16, 2024 $213.85 $216.45 $211.61 $214.73 309 357
Feb 15, 2024 $215.17 $216.33 $213.16 $214.54 404 303
Feb 14, 2024 $213.14 $214.67 $212.41 $214.43 259 640
Feb 13, 2024 $215.17 $216.17 $211.64 $213.75 346 533
Feb 12, 2024 $216.25 $216.76 $210.73 $216.25 409 615
Feb 09, 2024 $212.12 $212.36 $209.85 $212.34 247 123
Feb 08, 2024 $211.42 $212.48 $208.62 $211.74 371 573
Feb 07, 2024 $214.12 $214.20 $210.52 $210.76 246 483
Feb 06, 2024 $212.88 $215.82 $212.35 $214.95 258 627
Feb 05, 2024 $214.87 $214.87 $212.51 $212.76 211 443
Feb 02, 2024 $215.27 $215.27 $212.03 $213.41 274 951
Feb 01, 2024 $214.97 $217.72 $213.50 $215.97 289 661
Jan 31, 2024 $216.01 $218.92 $213.08 $214.78 334 146
Jan 30, 2024 $216.09 $216.87 $214.21 $215.02 223 945
Jan 29, 2024 $217.99 $218.67 $215.52 $216.91 296 780
Jan 26, 2024 $220.06 $221.81 $217.09 $218.01 217 128
Jan 25, 2024 $220.00 $222.38 $217.02 $219.32 306 168
Jan 24, 2024 $217.78 $219.82 $216.22 $218.81 288 511
Jan 23, 2024 $216.73 $218.77 $216.53 $217.79 299 229
Jan 22, 2024 $217.60 $218.57 $215.47 $216.24 301 188
Jan 19, 2024 $218.58 $218.92 $216.06 $217.84 338 837
Jan 18, 2024 $222.68 $222.75 $217.13 $219.11 357 088
Jan 17, 2024 $217.84 $222.30 $217.16 $222.25 321 467
Click to get the best stock tips daily for free!

About United Therapeutics Corporation

United Therapeutics United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin a... UTHR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT